Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms

Therapies for the Philadelphia chromosome-negative chronic myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), have generally been palliative and not curative. The only potentially curative therapy remains allogeneic hematopoietic stem-cell transplantation, but widespread application in patients with MPN is limited by factors that include disease stage, comorbidities, and donor availability [1,2].

Source: Leukemia Research - July 2, 2018 Category: Hematology Authors: J. Berdeja, F. Palandri, M.R. Baer, D. Quick, J.J. Kiladjian, G. Martinelli, A. Verma, O. Hamid, R. Walgren, C. Pitou, P.L. Li, A.T. Gerds Tags: Research paper Source Type: research